Alpha-1A adrenergic antagonist and phosphodiesterase-5 inhibitor combination

This page covers all Alpha-1A adrenergic antagonist and phosphodiesterase-5 inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Alpha-1A adrenergic receptor; phosphodiesterase-5 (PDE-5).

Targets

Alpha-1A adrenergic receptor; phosphodiesterase-5 (PDE-5)

Marketed (1)

• Tamsulosin and Tadalafil · Fayoum University Hospital · Urology
  Tamsulosin selectively blocks alpha-1A adrenergic receptors in the prostate to relax smooth muscle, while tadalafil inhibits phosphodiesterase-5 to increase cGMP and improve erectile function and lower urinary tract symptoms.

Patent intelligence

• alpha 1a adrenergic antagonist and phosphodiesterase 5 inhibitor combination patent landscape — aggregated cliff calendar, attackable patents, originator estates